Claudine Bruck, PhD
Dr Bruck, BioMotiv’s Project Leader, has a PhD in Biochemistry from University of Brussels. She was a post-doctoral student at Harvard University Medical School and an Assistant Professor at Tufts Medical School, before joining GlaxoSmithKline to build GSK’s HIV Vaccine Program (Rixensart, Belgium). In her role in GSK’s Vaccine group, she was also instrumental in the development of GSK’s HPV vaccine (Cervarix), and headed their cancer vaccine program from inception to phase 2, before joining the drug discovery group of GSK in King of Prussia, PA.
She held different roles in that group, from Head of Clinical Immunology (2004-2005) to VP and Head of Biology for the Center of Excellence for External Drug Discovery (2005-2008), to VP and Head of a newly formed Ophthalmology R&D group (2008-2015).
Besides her role at Biomotiv, Claudine is also co-founder and CEO of Prolifagen, a Start-Up company developing a microRNA-based drug for tissue regeneration and a course Director at University of Pennsylvania’s Institute of Translational Medicine and Applied Technology.